19295-57-9

Basic information

• Product Name: 3-hydroxy-2,2-dimethylpropanenitrile
• Synonyms: 3-hydroxy-2,2-dimethylpropanenitrile;propanenitrile, 3-hydroxy-2,2-dimethyl-;3-hydroxy-2,2-dimethyl-propionitrile
• CAS NO: 19295-57-9
• Molecular Formula: C₅H₉NO
• Molecular Weight: 99
• Mol File: 19295-57-9.mol

Chemical Properties

• Boiling Point: 86-87 °C(Press: 18 Torr)
• Appearance: /
• Density: 0.971±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.75±0.10(Predicted)
• CAS DataBase Reference: 3-hydroxy-2,2-dimethylpropanenitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-hydroxy-2,2-dimethylpropanenitrile(19295-57-9)
• EPA Substance Registry System: 3-hydroxy-2,2-dimethylpropanenitrile(19295-57-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 19295-57-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Hydroxy-2,2-dimethylpropanenitrile is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the formation of complex molecular structures.
Used in Adhesive Production:
3-Hydroxy-2,2-dimethylpropanenitrile is used as a component in the production of adhesives, where its chemical properties can enhance the bonding capabilities of the final product.
Used in Polymer Industry:
3-Hydroxy-2,2-dimethylpropanenitrile is used as a monomer or a building block in the synthesis of polymers, contributing to the development of new materials with specific properties.
Used in Dye Production:
3-Hydroxy-2,2-dimethylpropanenitrile is used as a precursor in the production of dyes, where its chemical structure can influence the color and stability of the resulting dyes.

Upstream product

• 630-18-2 tert-butyl isocyanide 
• 22426-30-8 2-cyano-2-methylpropanoic acid 
• 72291-30-6 methyl 2,2-dimethyl-cyanoacetate 
• 1572-98-1 2-cyano-2-methyl-propionic acid ethyl ester 
• 126-98-7 methacrylonitrile 
• 201230-82-2 carbon monoxide 
• 597-31-9 2,2-dimethyl-3-hydroxypropionaldehyde 
• 41296-71-3 3-acetoxy-2,2-dimethyl-propionitrile 
• 558-38-3 2-chloro-2-methyl-1-propanol 
• 143-33-9 sodium cyanide 
• 50-00-0 formaldehyd 
• 78-82-0 Isobutyronitrile 
• 36559-87-2 3-hydroxy-2,2-dimethylpropionaldoxime 

Downstream Products

• 26734-09-8 3-amino-2,2-dimethylpropan-1-ol 
• 157736-55-5 2,2-dimethyl-<<4-methylphenylsulfonyl>oxy>propanenitrile 
• 1458654-16-4 3-(4-bromo-3,5-dimethylphenoxy)-2,2-dimethylpropanenitrile 
• 7321-55-3 2,2-dimethylmalononitrile 
• 1432123-22-2 N²-phenoxyacetyl-5’-O-(4,4’-dimethoxytrityl)-2’-O-(2-cyano-2,2-dimethylethanimine-N-oxymethyl)guanosine 

Relevant articles and documents

Protein Modification at Tyrosine with Iminoxyl Radicals

Post-translational modifications (PTMs) of proteins are a biological mechanism for reversibly controlling protein function. Synthetic protein modifications (SPMs) at specific canonical amino acids can mimic PTMs. However, reversible SPMs at hydrophobic amino acid residues in proteins are especially limited. Here, we report a tyrosine (Tyr)-selective SPM utilizing persistent iminoxyl radicals, which are readily generated from sterically hindered oximes via single-electron oxidation. The reactivity of iminoxyl radicals with Tyr was dependent on the steric and electronic demands of oximes; isopropyl methyl piperidinium oxime 1f formed stable adducts, whereas the reaction of tert-butyl methyl piperidinium oxime 1o was reversible. The difference in reversibility between 1f and 1o, differentiated only by one methyl group, is due to the stability of iminoxyl radicals, which is partly dictated by the bond dissociation energy of oxime O-H groups. The Tyr-selective modifications with 1f and 1o proceeded under physiologically relevant, mild conditions. Specifically, the stable Tyr-modification with 1f introduced functional small molecules, including an azobenzene photoswitch, to proteins. Moreover, masking critical Tyr residues by SPM with 1o, and subsequent deconjugation triggered by the treatment with a thiol, enabled on-demand control of protein functions. We applied this reversible Tyr modification with 1o to alter an enzymatic activity and the binding affinity of a monoclonal antibody with an antigen upon modification/deconjugation. The on-demand ON/OFF switch of protein functions through Tyr-selective and reversible covalent-bond formation will provide unique opportunities in biological research and therapeutics.

General Asymmetric Synthesis of Densely Functionalized Pyrrolidines via Endo-Selective [3+2] Cycloaddition of β-Quaternary-Substituted Nitroalkenes and Azomethine Ylides

A scalable endo-selective synthesis of 2,3,4,5-tetrasubstituted pyrrolidines via cycloaddition of nitroalkenes and azomethine ylides is reported using a P,N-type ferrocenyl ligand and [Cu(OTf)]2·C6H6. The robust method is tolerant of a wide range of functionalities, including rarely reported quaternary nitroalkene substitution and heteroaromatic and hindered ortho-substituted arenes on the azomethine ylide. Subsequent transformations highlight the utility of the method in the synthesis of densely functionalized small molecules suitable for fragment-based drug discovery and the cystic fibrosis C2-corrector clinical candidate ABBV-3221.

BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF

Provided is a novel class of orally and/or topically available, selective and potent JAK inhibitors as safe and effective therapeutics against various diseases and disorders. Also provided is pharmaceutical composition of these compounds and methods of th

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compound and composition thereof, and uses of substituted heteroaryl compound and composition thereof

The present invention provides a substituted heteroaryl compound and a composition thereof, and uses of the substituted heteroaryl compound and the composition, wherein the compound is a compound represented by a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound represented by the formula (I). The present invention further provides a pharmaceutical composition containing the compound, wherein the pharmaceutical composition can regulate activity of protein kinases, particularly Aurora kinases and JAK kinases, and can be used for prevention, treatment, therapy and alleviation of protein kinases, particularly Aurora kinases and JAK kinase activity mediated diseases or disorders.

Method for preparing 2-amino-2-methyl-1-propanol

The invention relates to a method for preparing 2-amino-2-methyl-1-propanol. The method comprises the following steps: 1) enabling 2-chloropropane and sodium cyanide to react to generate 2-methyl propionitrile; 2) performing aldol condensation reaction on the 2-methyl propionitrile and formaldehyde so as to generate 2,2-dimethyl-3-hydroxy propionitrile; 3) performing hydrolysis reaction on 2,2-dimethyl-3-hydroxy propionitrile so as to generate 2,2-dimethyl-3-hydroxy propanamide; and 4) performing Hofmann degradation on the 2,2-dimethyl-3-hydroxy propanamide, thereby obtaining 2-amino-2-methyl-1-propanol. The method is cheap and easy in obtaining of raw materials of different steps, simple in reaction process, free of hash reaction condition, remarkable in cost advantage, high in yield, low in pollution and easy in product purification.

NOVEL COMPOUNDS

Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

The 2-cyano-2,2-dimethylethanimine-N-oxymethyl group for the 2′-hydroxyl protection of ribonucleosides in the solid-phase synthesis of RNA sequences

The reaction of 2-cyano-2-methyl propanal with 2′-O- aminooxymethylribonucleosides leads to stable and yet reversible 2′-O-(2-cyano-2,2-dimethylethanimine-N-oxymethyl)ribonucleosides. Following N-protection of the nucleobases, 5′-dimethoxytritylation and 3′-phosphitylation, the resulting 2′-protected ribonucleoside phosphoramidite monomers are employed in the solid-phase synthesis of three chimeric RNA sequences, each differing in their ratios of purine/pyrimidine. When the activation of phosphoramidite monomers is performed in the presence of 5-benzylthio-1H-tetrazole, coupling efficiencies averaging 99 % are obtained within 180 s. Upon completion of the RNA-chain assemblies, removal of the nucleobase and phosphate protecting groups and release of the sequences from the solid support are carried out under standard basic conditions, whereas the cleavage of 2′-O-(2-cyano-2,2-dimethylethanimine-N-oxymethyl) protective groups is effected (without releasing RNA alkylating side-products) by treatment with tetra-n-butylammonium fluoride (0.5 m) in dry DMSO over a period of 24-48 h at 55 °C. Characterization of the fully deprotected RNA sequences by polyacrylamide gel electrophoresis (PAGE), enzymatic hydrolysis, and matrix-assisted laser desorption/ionization (MALDI) mass spectrometry confirmed the identity and quality of these sequences. Thus, the use of 2′-O-aminooxymethylribonucleosides in the design of new 2′-hydroxyl protecting groups is a powerful approach to the development of a straightforward, efficient, and cost-effective method for the chemical synthesis of high-quality RNA sequences in the framework of RNA interference applications. Copyright

Pyrazole Compound

The present invention provides a pyrazole compound represented by the formula (I): wherein ring A0 is a pyrazole ring optionally further having 1 or 2 substituents; Ra is a substituted carbamoyl group; and Rb is an optionally substituted acylamino group, or a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of GSK-3β related pathology or disease, and a GSK-3β inhibitor including same.

PYRAZOLE COMPOUND

The present invention provides a pyrazole compound represented by the formula (I): wherein ring A0 is a pyrazole ring optionally further having 1 or 2 substituents; Ra is a substituted carbamoyl group; and Rb is an optionally substituted acylamino group, or a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of GSK-3β related pathology or disease, and a GSK-3β inhibitor including same.